RANKL inhibitors: A bright future?

Joint Bone Spine

Volumn 73, Issue 2, 2006, Pages 129-131

  Roux, Sophie ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Osteoprotegerin; RANK; RANK ligand; Resorption

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

BONE METASTASIS; BONE REMODELING; CELL INTERACTION; EDITORIAL; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; STROMA CELL;

ARTHRITIS, RHEUMATOID; BONE RESORPTION; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33645217436     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.10.015     Document Type: Editorial

References (21)

1. L.C. Hofbauer, S. Khosla, C.R. Dunstan, D.L. Lacey, W.J. Boyle, and B.L. Riggs The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J. Bone Miner. Res. 15 2000 2 12
2. S. Roux, and X. Mariette The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression Leuk. Lymphoma 45 2004 1111 1118
3. L. Huang, Y.Y. Cheng, L.T. Chow, M.H. Zheng, and S.M. Kumta Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases J. Clin. Pathol. 55 2002 877 878
4. E.M. Gravallese, C. Manning, A. Tsay, A. Naito, C. Pan, and E. Amento Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor Arthritis Rheum. 43 2000 250 258
5. T. Ikeda, M. Utsuyama, and K. Hirokawa Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones J. Bone Miner. Res. 16 2001 1416 1425
6. P.I. Croucher, C.M. Shipman, J. Lippitt, M. Perry, K. Asosingh, and A. Hijzen Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 98 2001 3534 3540
7. S. Morony, C. Capparelli, I. Sarosi, D.L. Lacey, C.R. Dunstan, and P.J. Kostenuik Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res. 61 2001 4432 4436
8. J.J. Body, P. Greipp, R.E. Coleman, T. Facon, F. Geurs, and J.P. Fermand A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 2003 887 892
9. K. Takeda, Y. Hayakawa, M.J. Smyth, N. Kayagaki, N. Yamaguchi, and S. Kakuta Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells Nat. Med. 7 2001 94 100
10. Y.Y. Kong, W.J. Boyle, and J.M. Penninger Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development Immunol. Cell Biol. 77 1999 188 193
11. J.G. Emery, P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, and C. Silverman Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J. Biol. Chem. 273 1998 14363 14367
12. T. Oba, X. Sun, B. Grubbs, Y. Cui, R. Kakonen, and T.A. Guise Effects of tumor secretion of recombinant osteoprotegerin on osteolytic metastases J. Bone Miner. Res. 16 suppl 1 2001 S192
13. M.C. Peterson, S.W. Martin, B.J. Stouch, D. Chen, D.L. Holloway, and J.J. Body ASCO 2004 (Abstract 4298)
14. Y.Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, and S. Morony Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 1999 304 309
15. E. Romas, N.A. Sims, D.K. Hards, M. Lindsay, J.W. Quinn, and P.F. Ryan Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis Am. J. Pathol. 161 2002 1419 1427
16. K. Redlich, S. Hayer, A. Maier, C.R. Dunstan, M. Tohidast-Akrad, and S. Lang Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin Arthritis Rheum. 46 2002 785 792
17. F. Eggelmeijer, S.E. Papapoulos, H.C. van Paassen, B.A. Dijkmans, R. Valkema, and M.L. Westedt Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a 3-year randomized, double-blind trial Arthritis Rheum. 39 1996 396 402
18. K. Song, Y. Chen, R. Goke, A. Wilmen, C. Seidel, and A. Goke Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression J. Exp. Med. 191 2000 1095 1104
19. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, P.T. Leese, and C.R. Dunstan The effect of a single dose of osteoprotegerin in postmenopausal women J. Bone Miner. Res. 16 2001 348 360
20. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, and P.T. Leese A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J. Bone Miner. Res. 19 2004 1059 1066
21. M.R. McClung, E.M. Lewiecki, M.A. Bolognese, G. Woodson, A. Moffett, and M. Peacock AMG 162 increases bone mineral density (BMD) within 1:month in postmenopausal women with low BMD J. Bone Miner. Res. 19 suppl 1 2004 S20